Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?
DOI:
https://doi.org/10.33393/jcb.2020.2164Keywords:
Biomarkers, Congestion, Diagnosis, Heart failure, Lung ultrasound, Primary careAbstract
Introduction: The association of pulmonary congestion assessed by lung ultrasound (LUS) and biomarkers—other than N-terminal pro-brain natriuretic peptide (NT-proBNP)—is uncertain.
Methods: We investigated the relationship between total B-line count by LUS and several biomarkers in outpatients with suspicion of heart failure (HF). Primary care patients with suspected new-onset nonacute HF were evaluated both with a 12-scan LUS protocol (8 anterolateral areas plus 4 lower posterior thoracic areas) and 11 inflammatory and cardiovascular biomarkers. A cardiologist blinded to LUS and biomarkers except NT-proBNP confirmed HF diagnosis. After log-transformation of biomarkers’ concentrations, unadjusted and adjusted correlations were performed.
Results: A total of 170 patients were included (age 76 ± 10 years, 67.6% women). HF diagnosis was confirmed in 38 (22.4%) patients. After adjustment by age, sex, body mass index, and renal function, total B-line sum significantly correlated with NT-proBNP (R = 0.29, p < 0.001), growth/differentiation factor-15 (GDF-15; R = 0.23, p = 0.003), high-sensitive Troponin T (hsTnT; R = 0.36, p < 0.001), soluble interleukin-1 receptor-like 1 (sST2; R = 0.29, p < 0.001), cancer antigen 125 (CA-125; R = 0.17, p = 0.03), high-sensitivity C-reactive protein (hsCRP; R = 0.20, p = 0.009), and interleukin (IL)-6 (R = 0.23, p = 0.003). In contrast, IL-33 (R = −0.01, p = 0.93), IL-1β (R = −0.10, p = 0.20), soluble neprilysin (sNEP; R = 0.09, p = 0.24), tumor necrosis factor-alpha (TNF-α; R = 0.07, p = 0.39), and TNF-α receptor superfamily member 1A (TNFRSF1A; R = 0.14, p = 0.07) did not.
Conclusions: Total B-line sum correlated significantly, although moderately, with congestion and several inflammation biomarkers. Unexpectedly, the highest correlation found was with hsTnT.
References
- Platz E, Jhund PS, Campbell RT, McMurray JJ. Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. Eur J Heart Fail. 2015;17:906-916.
- Berezin AE. Prognostication in different heart failure pheno-types: the role of circulating biomarkers. J Circ Biomark. 2016;5:6.
- Conangla L, Domingo M, Lupón J, et al. Lung ultrasound for heart failure diagnosis in primary care. J Card Fail. 2020 Jun 6:S1071-9164(19)31822-6. doi: 10.1016/j.cardfail.2020.04.019. Online ahead of print.
- Pascual-Figal DA, Bayes-Genis A, Asensio-Lopez MC, et al. The interleukin-1 axis and risk of death in patients with acutely decompensated heart failure. J Am Coll Cardiol. 2019;73:1016-1025.
- Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem. 2017;63:140-151.
- Myhre PL, Claggett B, Ballantyne CM, et al. Association between circulating troponin concentrations, left ventricular systolic and diastolic functions, and incident heart failure in older adults. JAMA Cardiol. 2019;4:997-1006.
- Núñez J, Bayés-Genís A, Revuelta-López E, et al. Clinical role of CA125 in worsening heart failure: a BIOSTAT-CHF study subanalysis. JACC Heart Fail. 2020;8:386-397.